CVRx said it added $12 million from DaVita HealthCare, Ysios Capital and others to its Series F funding round, taking the total for the round to $42 million.
The Minneapolis-based company is planning to use the money to advance clinical trials and expand its international commercial footprint, according to a press release. CVRx developed the Barostim Neo, a pacemaker-like device designed to treat hypertension.
The Series F round included contributions from new investors Ysios Capital and DaVita HealthCare Partners, according to the release. Ysios general partner Josep Sanfeliu will take a seat on the CVRx board, the company said.
“CVRx is recognized as a strong, innovative leader. I am excited to join the board of directors as a European active medtech investor and look forward to working with the CVRx team to build upon their clinical and commercial success,” Sanfeliu said in prepared remarks.
The Barostim Neo device won CE Mark approval in the European Union in July 2012.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!